Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
暂无分享,去创建一个
D. Dearnaley | C. Parker | C. Cooper | R. A’Hern | S. Kaye | L. Terstappen | D. Olmos | J. Swennenhuis | J. D. de Bono | G. Attard | C. Jameson | M. Cox | R. Riisnaes | A. Molina | A. Reid | F. Coumans | Rianne Levink | R. Sipkema | C. Carden | N. Oommen | E. Thompson | J. Moreira | G. Hawche | Elaine Vickers
[1] Kenneth J. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment , 2009 .
[2] L. Terstappen,et al. Characterization of circulating tumor cells by fluorescence in situ hybridization , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[3] D. Dearnaley,et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Mitch Dowsett,et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[6] R. Shah,et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.
[7] J. Cuzick,et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.
[8] T. Kroll,et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[10] S. Varambally,et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.
[11] S. Digumarthy,et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.
[12] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[13] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[14] J. Kreisberg,et al. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. , 2007, Current cancer drug targets.
[15] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[16] C. Parker,et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development , 2006, British Journal of Cancer.
[17] Arul M Chinnaiyan,et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.
[18] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[19] J. Veltman,et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines , 2004, Genes, chromosomes & cancer.
[20] Jan Greve,et al. Imaging technique implemented in CellTracks system. , 2002, Cytometry.
[21] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.
[23] A. Weiss,et al. Detection and characterization of carcinoma cells in the blood. , 1998, Proceedings of the National Academy of Sciences of the United States of America.